AnPac Bio Completed 1st Half Year with Increased ASP and Revenue

SAN JOSE, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, pre-announced certain results from the quarter ending 6/30/20. The Company performed 6,500 paid tests in June 2020, which was almost 50% higher than the average monthly paid tests in 2019.  Based on unaudited numbers for the first half of the year in 2020 through 6/30/20, revenue was slightly higher compared to the same period in 2019, while the average selling price (ASP) increased as well over 2019.  AnPac Bio plans to file the 1st half year results on August 28, 2020.  

Click to view original post